Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Allakos Inc. ALLK

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Recent & Breaking News (NDAQ:ALLK)

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

GlobeNewswire May 24, 2021

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 10, 2021

Allakos Appoints Baird Radford as Chief Financial Officer

GlobeNewswire April 19, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

GlobeNewswire March 30, 2021

Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

GlobeNewswire March 1, 2021

Allakos Appoints Natalie Holles to its Board of Directors

GlobeNewswire December 22, 2020

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 9, 2020

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

GlobeNewswire November 2, 2020

Allakos Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 28, 2020

Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020

GlobeNewswire October 27, 2020

Allakos Announces Proposed Public Offering of Common Stock

GlobeNewswire October 27, 2020

Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed

GlobeNewswire October 26, 2020

Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

GlobeNewswire October 26, 2020

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

GlobeNewswire October 21, 2020

Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire August 10, 2020

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of the Following Companies: Allakos, Inc. (Nasdaq - ALLK), Enphase Energy, Inc. (Nasdaq - ENPH), MoSys, Inc. (Nasdaq - MOSY)

ACCESSWIRE IA June 16, 2020

Allakos Initiates Patient Recruitment for AK002 Registrational Studies

GlobeNewswire June 3, 2020

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020

GlobeNewswire May 21, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allakos Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile May 11, 2020

ALLK DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Allakos Inc. Investors of Class Action and Lead Plaintiff Deadline: May 11, 2020

ACCESSWIRE IA May 11, 2020